28
Participants
Start Date
August 31, 2008
Primary Completion Date
March 31, 2010
Study Completion Date
March 31, 2010
Sunitinib malate
Sunitinib malate 37.5 mg orally, daily
Paclitaxel
Paclitaxel 90 mg/m2 IV on days 1, 8 and 15.
Ireland Cancer Center - University Hospitals of Cleveland, Cleveland
IN Onc/Hem Associates, Indianapolis
Indiana University Simon Cancer Center, Indianapolis
Monroe Medical Associates, Munster
Northern Indiana Cancer Research Consortium, South Bend
Fort Wayne Oncology & Hematology, Inc, Fort Wayne
Medical Consultants, P.C., Muncie
Cancer Care Center of Southern Indiana, Bloomington
Oncology Hematology Associates of SW Indiana, Evansville
Providence Medical Group, Terre Haute
Arnett Cancer Care, Lafayette
Horizon Oncology Center, Lafayette
Northwestern University Feinberg School of Medicine, Chicago
Rush-Presbyterian St. Luke's Medical Center, Chicago
Medical & Surgical Specialists, LLC, Galesburg
Lead Sponsor
Collaborators (1)
Pfizer
INDUSTRY
Hoosier Cancer Research Network
OTHER